Population pharmacokinetics of levosimendan in patients with congestive heart failure
Open Access
- 12 May 2003
- journal article
- clinical trial
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 55 (6) , 544-551
- https://doi.org/10.1046/j.1365-2125.2003.01778.x
Abstract
Aims The aim of this study was to characterize the population pharmacokinetics of levosimendan in patients with heart failure (NYHA grades III and IV) and its relationship to demographic factors, disease severity and concomitant use of digoxin and β‐blocking agents.Methods Data from two efficacy studies with levosimendan administered by intravenous infusion were combined (190 patients in total). The data were analysed using a nonlinear mixed‐effects modelling approach as implemented in the NONMEM program. The model development was done in three sequential steps. First the best structural model was determined (e.g. a one‐, two‐ or three‐compartment pharmacokinetic model). This was followed by the identification and incorporation of important covariates into the model. Lastly the stochastic part of the model was refined.Results A two‐compartment model best described levosimendan pharmacokinetics. Clearance and the central volume of distribution were found to increase linearly with bodyweight. No other covariates, including concomitant use of digoxin and β‐blocking agents, influenced the pharmacokinetics. In the final model, a 76‐kg patient was estimated to have a clearance ± s.e. of 13.3 ± 0.4 l h−1 and a central volume of distribution of 16.8 ± 0.79 l. The interindividual variability was estimated to be 39% and 60% for clearance and central volume of distribution, respectively. Weight changed clearance by 1.5% [95% confidence interval (CI) 0.9%, 2.1%] and the central volume of distribution by 0.9% (95% CI 0.5%, 1.3%) per kg.Conclusions The population pharmacokinetics parameters of levosimendan in this patient group were comparable to those obtained by traditional methods in healthy volunteers and patients with mild heart failure. Bodyweight influenced the clearance and the central volume of distribution, which in practice is accounted for by weight adjusting doses. None of the other covariates, including digoxin and β‐blocking agents, significantly influenced the pharmacokinetics of levosimendan.Keywords
This publication has 23 references indexed in Scilit:
- Levosimendan: a parenteral calcium-sensitising drug with additional vasodilatory propertiesExpert Opinion on Investigational Drugs, 2001
- Acute Hemodynamic and Clinical Effects of Levosimendan in Patients With Severe Heart FailureCirculation, 2000
- Effects of levosimendan on cardiac arrhythmia: electrophysiologic and ambulatory electrocardiographic findings in phase II and phase III clinical studies in cardiac failureThe American Journal of Cardiology, 1999
- Xpose—an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEMComputer Methods and Programs in Biomedicine, 1998
- Troponin C-mediated calcium sensitization by levosimendan accelarates the proportional development of isometric tensionJournal of Molecular and Cellular Cardiology, 1995
- Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendanJournal of Molecular and Cellular Cardiology, 1995
- Pharmacokinetics of Levosimendan in Healthy Volunteers and Patients with Congestive Heart FailureJournal of Cardiovascular Pharmacology, 1995
- Building population pharmacokineticpharmacodynamic models. I. Models for covariate effectsJournal of Pharmacokinetics and Biopharmaceutics, 1992
- Clinical Pharmacokinetics in Heart FailureClinical Pharmacokinetics, 1988
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976